Hot Topics and Issues in the Biosimilars Space: Part II

Reference Material:
An Update on the BPCIA and the "Patent Dance" (21 Pages)

As the eighth anniversary of the BPCIA approaches, developments in the biosimilars space have seized national attention. The Supreme Court has interpreted the “patent dance” and “notice of commercial marketing” provisions of the BPCIA in Sandoz Inc. v. Amgen Inc., and the FDA has currently approved nine biosimilar drug products.  In this second installment of the February 2016 program, the panel will discuss recent case law and updates in FDA implementation and policy development.  Strategies for clearing intellectual property hurdles involving biologics in inter partes reviews and the mechanics of the patent dance will also be addressed.

Please join us for an active and engaging discussion of the future of biosimilars.

Panelists
Chad Landmon, Partner, Axinn, Veltrop & Harkrider LLP 
Brian Murphy, Partner, Haug Partners LLP
Christine Simmon, Senior Vice President, Policy & Strategic Alliances Executive Director, Biosimilars Council, Association for Accessible Medicines

Moderator: Michael Johnson, Partner, Willkie Farr & Gallagher LLP

Program Schedule
6:00 p.m. – 6:30 p.m. Registration & Pre-reception
6:30 p.m. – 8:00 p.m. Presentation 
8:00 p.m. – 8:30 p.m. Post-reception

Sponsored by

Sponsorship Opportunities

NYIPLA reaches a diverse community of intellectual property professionals through a wide range of programs and activities that can provide a rewarding sponsorship experience. Benefits include: sponsor recognition, logo displays, promotional materials, and more. Click HERE for Sponsorship details.